본문 바로가기

A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
SCIENTIFIC REPORTS12(1) · 2022
피인용
Web of Science 11Scopus 10
FWCI (Scopus)
0.39
JCR IF
JCR 2021 4.997
ISSN
2045-2322

저자

  1. 이지은제1저자Pusan Natl Univ, Sch Med, Dept Ophthalmol, Yangsan Hosp, Yangsan, South Korea
  2. 김상윤Pusan Natl Univ, Sch Med, Dept Ophthalmol, Yangsan Hosp, Yangsan, South Korea
  3. Lee, Hyung KeunYonsei Univ, Inst Vis Res, Dept Ophthalmol, Coll Med, Seoul 06273, South Korea
  4. Chung, Tae-YoungSungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, Seoul, South Korea
  5. Kim, Jae YongUniv Ulsan, Asan Med Ctr, Dept Ophthalmol, Coll Med, Seoul, South Korea
  6. Choi, Chul YoungSungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Ophthalmol, Seoul 03181, South Korea
  7. Chung, So HyangCatholic Univ Korea, Coll Med, Dept Ophthalmol, Seoul, South Korea
  8. Kim, Dong HyunGachon Univ, Gil Med Ctr, Dept Ophthalmol, Coll Med, Incheon, South Korea
  9. Kim, Kyoung WooChung Ang Univ, Chung Ang Univ Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea
  10. Chung, Jin KwonSoonchunhyang Univ, Coll Med, Dept Ophthalmol, Seoul Hosp, Seoul 140743, South Korea
  11. Hwang, Kyu YeonKimS Eye Hosp, Dept Ophthalmol, Seoul, South Korea
  12. Hwang, Ho SikCatholic Univ Korea, Coll Med, Dept Ophthalmol, Yeouido St Marys Hosp, Seoul, South Korea
  13. Kim, Jin HyoungInje Univ, Ilsan Paik Hosp, Dept Ophthalmol, Coll Med, Goyang, South Korea
  14. Hyon, Joon Young교신저자Seoul Natl Univ, Coll Med, Dept Ophthalmol, Bundang Hosp, 82 Gumi Ro 173Beon-gil, Seongnam Si, Gyeonggi Do, South Korea

초록

© 2022, The Author(s).Hyaluronic acid (HA) and cyclosporine A (CsA) eyedrops are commonly prescribed in dry eye syndrome (DES). The effectiveness of each preparation in DES is well-known, yet the superiority of one over another has been studied little. We assessed the efficacy and tolerability of 0.15% HA compared to combinations of 0.05% CsA plus 0.5% carboxymethylcellulose (CMC), and 0.15% HA plus 0.05% CsA in patients with moderate to severe DES. Total 438 patients with moderate to severe DES were recruited and randomized for one of the three treatments for 12 weeks. Effectiveness was assessed at baseline, 4- and 12-weeks. The primary endpoint was change in corneal staining score. The secondary endpoints were tear break-up time (TBUT), strip meniscometry (SM) score, ocular surface disease index (OSDI) score, and tolerability questionnaire. The change in corneal staining score for 0.15% HA from the baseline was non-inferior to that of 0.05% CsA. Corneal staining score, TBUT, SM score, and OSDI score improved in all groups without statistically significant intergroup differences. Better tolerability and lower prevalence of adverse drug reactions were seen in 0.15% HA. Our findings suggest that 0.15% HA may be equivalently effective and safer than 0.05% CsA in treating moderate to severe DES.

키워드

SODIUM HYALURONATEOCULAR SURFACETOPICAL CYCLOSPORINETEAR FILMMODERATESAFETYFLUORESCEINEYEDROPSDISEASEQUALITY

식별자

Scopus EID
2-s2.0-85141163409
WoS UID
000879109400099